JLE

Journal de Pharmacie Clinique

MENU

Retour d’expérience sur l’utilisation du belimumab en conditions réelles dans le cadre du traitement de patients lupiques Volume 39, numéro 3, Septembre 2020

  • [1] Blair H.A., Duggan S.T. Belimumab: a review in systemic lupus erythematosus. Drugs. 2018;78:355-366. 3
  • [2] Felten R., Dervovic E., Chasset F. The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials. Autoimmun Rev. 2018;17:781-790. 8
  • [3] Chasset F., Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2018;17:44-52. 1
  • [4] European Medicines Agency. Benlysta (belimumab): summary of product characteristics [Internet]. European Medicines Agency, 2017. http://www.ema.europa.eu
  • [5] Wallace D., Navarra S., Petri M. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22:144-154. 2
  • [6] HAS. Direction de l’Évaluation Médicale, Economique et de Santé Publique. Commision de la Transparence – Avis du 25 Juin 2014. HAS, 2014.
  • [7] Amoura Z, Filière de Santé des Maladies Auto-Immunes et AutoInflammatoires Rares (FAI2R). Protocole National de Diagnostic et de Soins (PNDS). Lupus systémique [Internet]. FAI2R, 2017. https://www.has-sante.fr/portail/upload/docs/application/pdf/2017-03/dir1/pnds_-_lupus_systemique.pdf
  • [8] Askanase A.D., Yazdany J., Molta C.T. Post-marketing experiences with belimumab in the treatment of SLE patients. Rheum Dis Clin N Am. 2014;40:507-517. 3
  • [9] Ginzler E.M., Wallace D.J., Merrill J.T. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:300-309. 2
  • [10] Trentin F., Gatto M., Zen M. Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: a review of observational clinical-practice-based studies. Clin Rev Allergy Immunol. 2018;54:331-343. 2
  • [11] Yazdany J, Erkan D, Sanchez-Guerrero J, et al. Post-marketing experience with belimumab in U.S. lupus centers: data from the lupus clinical trials consortium, Inc. (LCTC) national patient registry [Internet]. American College of Rheumatology, 2013. https://acrabstracts.org/abstract/post-marketing-experience-with-belimumab-in-u-s-lupus-centers-data-from-the-lupus-clinical-trials-consortium-inc-lctc-national-patient-registry/
  • [12] Scheinberg M., Golmia R. Real life experience on the effect of Belimumab in patients with active systemic lupus. Springer Plus. 2014;3:758. 1
  • [13] Scheinberg M., de Melo F.F.N., Bueno A.N. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol. 2016;35:1719-1723. 7
  • [14] Collins C.E., Dall’Era M., Kan H. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118. 1
  • [15] Cortés J., Andreu J.L., Calvo J. Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health. 2014;17:A534. 7
  • [16] Schwarting A., Schroeder J.O., Alexander T. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany study. Rheumatol Ther. 2016;3:271-290. 2
  • [17] Touma Z., Sayani A., Pineau C.A. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study. Rheumatol Int. 2017;37:865-873. 6
  • [18] von Kempis J., Duetsch S., Reuschling N. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland. Swiss Med Wkly. 2019;149:w20022.
  • [19] Garval E., Pennaforte J.-L., Jaussaud R. Traitement du lupus érythémateux par le bélimumab en pratique courante : étude rétrospective de 15 malades. Ann Dermatol Venereol. 2018;145:5-12. 1
  • [20] Iaccarino L., Andreoli L., Bocci E.B. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2017;86:1-8.
  • [21] GlaxoSmithKline. Benlysta (belimumab): U.S. prescribing information [Internet]. GlaxoSmithKline, 2017. https://www.accessdata.fda.gov
  • [22] Parodis I., Sjöwall C., Jönsen A. 103 Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. BMJ. 2017;4:A43-A44. 1
  • [23] Chasset F., Francès C., Arnaud L. Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus. J Am Acad Dermatol. 2015;73:e81. 2
  • [24] Babini A, Garcia MA, Barreira JC, et al. Evaluation of use of belimumab in clinical practice settings: results in Argentina [Internet]. American College of Rheumatology, 2016. https://acrabstracts.org/abstract/evaluation-of-use-of-belimumab-in-clinical-practice-settings-results-in-argentina/